Highlights and Quick Summary
- Net Aquisitions for the quarter ending December 30, 2018 was $0 (a NaN% decrease compared to previous quarter)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Net Aquisitions of Entera Bio Ltd.Most recent Net Aquisitionsof ENTX including historical data for past 10 years.
Interactive Chart of Net Aquisitions of Entera Bio Ltd.
Entera Bio Ltd. Net Aquisitions for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Business Profile of Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.